SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Dukat Andre)
 

Sökning: WFRF:(Dukat Andre) > (2023) > IGFBP-7 and Outcome...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004861naa a2200733 4500
001oai:DiVA.org:uu-512637
003SwePub
008240522s2023 | |||||||||||000 ||eng|
009oai:gup.ub.gu.se/323085
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5126372 URI
0247 a https://doi.org/10.1016/j.jchf.2022.09.0042 DOI
0247 a https://gup.ub.gu.se/publication/3230852 URI
040 a (SwePub)uud (SwePub)gu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Adamson, Carly4 aut
2451 0a IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction :b Findings From DAPA-HF.
264 1b Elsevier BV,c 2023
338 a print2 rdacarrier
520 a BACKGROUND: Insulin-like growth factor-binding protein-7 (IGFBP-7) has been proposed as a potential prognostic biomarker in heart failure (HF), but the association between elevation in IGFBP-7 and HF outcomes in ambulant patients with heart failure with reduced ejection fraction (HFrEF) is unknown. OBJECTIVES: The authors addressed this question in a post hoc analysis of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial. METHODS: The primary outcome was a composite of cardiovascular death or a worsening HF event. The risk of adverse outcome was compared across tertiles of IGFBP-7 concentration by means of Cox proportional hazard models adjusted for N-terminal pro-B- type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hsTnT). The efficacy of randomized treatment across IGFBP-7 tertiles was assessed. Change in IGFBP-7 at 12 months was compared with the use of geometric means. RESULTS: A total of 3,158 patients had IGFBP-7 measured at baseline, and 2,493 had a repeated measure at 12 months. Patients in the highest tertile of IGFBP-7 had evidence of more advanced HFrEF. The adjusted HR for the primary endpoint in tertile 3, compared with tertile 1, was 1.48 (95% CI: 1.17-1.88). There was no modification of the benefit of dapagliflozin by baseline IGFBP-7 (P interaction = 0.34). Dapagliflozin did not change IGFBP-7 levels over 1 year (P = 0.34). CONCLUSIONS: Higher IGFBP-7 in patients with HFrEF was associated with worse clinical profile and an increased risk of adverse clinical outcomes. IGFBP-7 provided prognostic information incremental to clinical variables, NT-proBNP, and hsTnT. The benefit of dapagliflozin was not modulated by IGFBP-7 level. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124).
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
653 a *Heart Failure/drug therapy
653 a *Ventricular Dysfunction
653 a Left
653 a biomarker
653 a dapagliflozin
653 a heart failure
653 a Humans
653 a Insulin-Like Growth Factor Binding Proteins
653 a insulin-like growth factor-binding protein-7
653 a Proportional Hazards Models
653 a SGLT2 inhibitor
653 a Stroke Volume
7001 a Welsh, Paul4 aut
7001 a Docherty, Kieran F.4 aut
7001 a de Boer, Rudolf A.4 aut
7001 a Diez, Mirta4 aut
7001 a Drozdz, Jaroslaw4 aut
7001 a Dukat, Andre4 aut
7001 a Inzucchi, Silvio E.4 aut
7001 a Kober, Lars4 aut
7001 a Kosiborod, Mikhail N.4 aut
7001 a Ljungman, Charlotta,d 1977u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xljcha
7001 a Martinez, Felipe A.4 aut
7001 a Ponikowski, Piotr4 aut
7001 a Sabatine, Marc S.4 aut
7001 a Morrow, David A.4 aut
7001 a Lindholm, Daniel4 aut
7001 a Hammarstedt, Ann4 aut
7001 a Boulton, David W.4 aut
7001 a Greasley, Peter J.4 aut
7001 a Langkilde, Anna Maria4 aut
7001 a Solomon, Scott D.4 aut
7001 a Sattar, Naveed4 aut
7001 a McMurray, John J. V.4 aut
7001 a Jhund, Pardeep S.4 aut
7102 a Göteborgs universitetb Institutionen för medicin, avdelningen för molekylär och klinisk medicin4 org
7730 t JACC. Heart failured : Elsevier BVg 11:3, s. 291-304q 11:3<291-304x 2213-1779x 2213-1787
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-512637
8564 8u https://doi.org/10.1016/j.jchf.2022.09.004
8564 8u https://gup.ub.gu.se/publication/323085

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy